https://doi.org/10.4081/itjm.2011.120

Agranulocytosis: an adverse effect of allopurinol treatment

Vol. 5 No. 2 (2011)
Submitted: 7 March 2013
Accepted: 7 March 2013
Published: 7 March 2013
Allopurinol, Agranulocytosis, Hyperuricaemia.
Abstract Views: 1462
PDF: 1421
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Elisa Mari
Franco Ricci
Davide Imberti
Massimo Gallerani
m.gallerani@ospfe.it
Introduction: Allopurinol is a xanthine oxidase inhibitor that is primarily used to treat hyperuricemia and its complications. The drug is rarely associated with adverse effects, but those that occur can be significant. Hematologic side effects, including bone marrow suppression, severe anemia, thrombocytopenia, and leukopenia, have been reported in 0.2-0.6% of treated patients.
Materials and methods: We report a case of agranulocytosis associated with allopurinol therapy in a patient admitted for fever.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

PlumX Metrics

PlumX Metrics  provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Mari, E., Ricci, F., Imberti, D., & Gallerani, M. (2013). Agranulocytosis: an adverse effect of allopurinol treatment. Italian Journal of Medicine, 5(2), 120–123. https://doi.org/10.4081/itjm.2011.120

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.